NO20074421L - Nukleinsyrekonstrukter - Google Patents
NukleinsyrekonstrukterInfo
- Publication number
- NO20074421L NO20074421L NO20074421A NO20074421A NO20074421L NO 20074421 L NO20074421 L NO 20074421L NO 20074421 A NO20074421 A NO 20074421A NO 20074421 A NO20074421 A NO 20074421A NO 20074421 L NO20074421 L NO 20074421L
- Authority
- NO
- Norway
- Prior art keywords
- hcmv
- immediate early
- promoter sequence
- chimeric promoter
- exon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64838205P | 2005-02-01 | 2005-02-01 | |
US67249705P | 2005-04-19 | 2005-04-19 | |
GBGB0507997.5A GB0507997D0 (en) | 2005-02-01 | 2005-04-20 | Nucleic acid constructs |
PCT/GB2006/000344 WO2006082398A2 (fr) | 2005-02-01 | 2006-02-01 | Constructions d'acide nucleique |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20074421L true NO20074421L (no) | 2007-10-31 |
Family
ID=36178086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074421A NO20074421L (no) | 2005-02-01 | 2007-08-30 | Nukleinsyrekonstrukter |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100221349A1 (fr) |
EP (1) | EP1850869A2 (fr) |
JP (1) | JP2008528020A (fr) |
KR (1) | KR20070100403A (fr) |
CN (1) | CN101155597A (fr) |
AP (1) | AP2007004137A0 (fr) |
AU (1) | AU2006210716A1 (fr) |
BR (1) | BRPI0607119A2 (fr) |
CA (1) | CA2596731A1 (fr) |
EA (1) | EA011557B1 (fr) |
GB (1) | GB0507997D0 (fr) |
IL (1) | IL184653A0 (fr) |
MA (1) | MA29274B1 (fr) |
MX (1) | MX2007009164A (fr) |
NI (1) | NI200700191A (fr) |
NO (1) | NO20074421L (fr) |
SG (1) | SG158902A1 (fr) |
TN (1) | TNSN07295A1 (fr) |
WO (1) | WO2006082398A2 (fr) |
ZA (1) | ZA200707522B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004279991B2 (en) | 2003-10-10 | 2010-11-25 | Powderject Vaccines, Inc. | Nucleic acid constructs |
EP1957982A2 (fr) * | 2005-12-05 | 2008-08-20 | Guava Technologies, Inc. | Characterisation d'analyse a base particulaire |
EP1925318A1 (fr) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Vaccin à base de virus modifié de vaccin Ankara (MVA) recombinant contre la grippe aviaire |
US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
HUE031422T2 (en) * | 2007-09-26 | 2017-07-28 | Intrexon Corp | Artificial 5'UTRs, expression vectors, and methods for increasing transgene expression |
US9592285B2 (en) | 2007-11-12 | 2017-03-14 | The Trustees Of The University Of Pennsylvania | Vaccines against multiple subtypes of influenza virus |
WO2009092038A1 (fr) * | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccination a base d'adn de la grippe et methodes d'utilisation associees |
WO2010060430A2 (fr) * | 2008-11-28 | 2010-06-03 | Statens Serum Institut | Vaccins optimises contre la grippe |
US10022431B2 (en) | 2010-02-10 | 2018-07-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US9517258B2 (en) * | 2012-03-15 | 2016-12-13 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN105219773B (zh) * | 2013-12-25 | 2017-09-26 | 北京大北农科技集团股份有限公司 | 嵌合启动子及其用途 |
CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
EP3119426A4 (fr) | 2014-03-19 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Méthodes et matériels pour le traitement du cancer |
WO2015143223A1 (fr) | 2014-03-19 | 2015-09-24 | Mayo Foundation For Medical Education And Research | Procédés et matériel pour traiter le cancer |
CN105120042B (zh) * | 2015-09-09 | 2019-02-12 | 小米科技有限责任公司 | 移动终端 |
WO2017059902A1 (fr) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | Séquences utr 3' permettant la stabilisation d'arn |
US20210187064A1 (en) * | 2018-05-07 | 2021-06-24 | Administrators Of The Tulane Educational Fund | Mutated e. coli enterotoxins as anti-inflammatory agents |
US20240084267A1 (en) * | 2021-01-12 | 2024-03-14 | Duke University | Compositions and methods for the genetic manipulation of the influenza virus |
WO2024097894A1 (fr) * | 2022-11-04 | 2024-05-10 | RNAimmune, Inc. | Compositions et procédés de vaccins à base d'acide ribonucléique codant nye-so-1 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3431140A1 (de) * | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5120657A (en) * | 1986-12-05 | 1992-06-09 | Agracetus, Inc. | Apparatus for genetic transformation |
US5204253A (en) * | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
CA2158733C (fr) * | 1994-01-21 | 2007-01-16 | Dennis E. Mccabe | Instrument de depot de genes par entrainement gazeux |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
CN1247785C (zh) * | 2000-10-13 | 2006-03-29 | 希龙公司 | 巨细胞病毒内含子a片段 |
MXPA03004638A (es) * | 2000-11-27 | 2004-04-20 | Powderject Vaccines Inc | Adyuvantes de acido nucleico. |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
AU2004279991B2 (en) * | 2003-10-10 | 2010-11-25 | Powderject Vaccines, Inc. | Nucleic acid constructs |
AU2004280630A1 (en) * | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc. | Method |
-
2005
- 2005-04-20 GB GBGB0507997.5A patent/GB0507997D0/en not_active Ceased
-
2006
- 2006-02-01 EA EA200701643A patent/EA011557B1/ru not_active IP Right Cessation
- 2006-02-01 US US11/815,278 patent/US20100221349A1/en not_active Abandoned
- 2006-02-01 JP JP2007552730A patent/JP2008528020A/ja active Pending
- 2006-02-01 WO PCT/GB2006/000344 patent/WO2006082398A2/fr active Application Filing
- 2006-02-01 AU AU2006210716A patent/AU2006210716A1/en not_active Abandoned
- 2006-02-01 SG SG201000360-6A patent/SG158902A1/en unknown
- 2006-02-01 MX MX2007009164A patent/MX2007009164A/es unknown
- 2006-02-01 CN CNA2006800110768A patent/CN101155597A/zh active Pending
- 2006-02-01 CA CA002596731A patent/CA2596731A1/fr not_active Abandoned
- 2006-02-01 AP AP2007004137A patent/AP2007004137A0/xx unknown
- 2006-02-01 EP EP06704134A patent/EP1850869A2/fr not_active Withdrawn
- 2006-02-01 BR BRPI0607119-8A patent/BRPI0607119A2/pt not_active IP Right Cessation
- 2006-02-01 KR KR1020077019899A patent/KR20070100403A/ko not_active Application Discontinuation
-
2007
- 2007-07-17 IL IL184653A patent/IL184653A0/en unknown
- 2007-07-30 TN TNP2007000295A patent/TNSN07295A1/en unknown
- 2007-07-30 NI NI200700191A patent/NI200700191A/es unknown
- 2007-08-28 MA MA30172A patent/MA29274B1/fr unknown
- 2007-08-30 NO NO20074421A patent/NO20074421L/no not_active Application Discontinuation
- 2007-08-31 ZA ZA200707522A patent/ZA200707522B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006082398A2 (fr) | 2006-08-10 |
CA2596731A1 (fr) | 2006-08-10 |
US20100221349A1 (en) | 2010-09-02 |
TNSN07295A1 (en) | 2008-12-31 |
MA29274B1 (fr) | 2008-02-01 |
SG158902A1 (en) | 2010-02-26 |
GB0507997D0 (en) | 2005-05-25 |
MX2007009164A (es) | 2008-03-13 |
BRPI0607119A2 (pt) | 2009-08-11 |
EA011557B1 (ru) | 2009-04-28 |
KR20070100403A (ko) | 2007-10-10 |
NI200700191A (es) | 2008-02-05 |
EA200701643A1 (ru) | 2008-02-28 |
IL184653A0 (en) | 2007-12-03 |
EP1850869A2 (fr) | 2007-11-07 |
WO2006082398A3 (fr) | 2006-10-19 |
AU2006210716A1 (en) | 2006-08-10 |
AP2007004137A0 (en) | 2007-08-31 |
CN101155597A (zh) | 2008-04-02 |
ZA200707522B (en) | 2008-08-27 |
JP2008528020A (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074421L (no) | Nukleinsyrekonstrukter | |
NO20062080L (no) | Nukleinsyrekonstrukter | |
TW200510446A (en) | Corn event TC1507 and methods for detection thereof | |
PT1597391E (pt) | Utilização de arn intrónico para medir a expressão genética | |
WO2007014275A3 (fr) | Integration et expression ciblees de sequences d'acides nucleiques exogenes | |
EA201301069A1 (ru) | Событие 5307 кукурузы | |
MX2007010036A (es) | Maiz evento 3272 y metodos para la deteccion del mismo. | |
DK1471926T3 (da) | Sammensætninger og fremgangsmåder til terapeutisk anvendelse af en atonal-associeret sekvens | |
PL1941045T3 (pl) | Zastosowanie sekwencji kwasu nukleinowego do wytwarzania transgenicznej rośliny o zwiększonej tolerancji na suszę | |
GB0317466D0 (en) | Use | |
UA97088C2 (ru) | Трансгенная кукуруза das-59122-7, стойкая к насекомым, и способы его обнаружения | |
EP1859046A4 (fr) | Vecteur d'expression pour cellule animale comprenant au moins une copie de sequences d'adn mar au terminal 3' de la region de terminaison de transcription d'un gene et technique d'expression d'un gene etranger au moyen dudit vecteur | |
EP1828404A4 (fr) | Dispositifs et procédés permettant de déterminer l'activité d'une protéase | |
EP1477560A4 (fr) | Promoteur, intron et terminateur d'origine algale | |
MX2021004455A (es) | Composiciones y métodos para administrar transgenes. | |
MX2009006681A (es) | Composiciones y metodos para la expresion de acidos nucleicos. | |
CY1116649T1 (el) | Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα | |
UA92913C2 (ru) | Экспрессионный вектор и способы продуцирования высоких уровней белков | |
WO2007046787A3 (fr) | Methodes permettant de reduire l'extinction induite par des repetitions de l'expression d'un transgene et biocapteurs fluorescents ameliores | |
DE50110723D1 (de) | Isolierte luziferasen sowie deren verwendung | |
WO2003047532A3 (fr) | Compositions et methodes destinees a l'utilisation therapeutique d'une sequence associee au gene atonal pour une maladie gastro-intestinale | |
DE10342670A1 (de) | Isoliertes Photoprotein mtClytin, sowie dessen Verwendung | |
TW200628611A (en) | Nucleic acid constructs | |
MXPA05006983A (es) | Promotor artificial para la expresion de secuencias de acido desoxirribonucleico en celulas vegetales. | |
ATE401399T1 (de) | Nukleinsäure für einen klonierungsvektor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |